Phaseline

Targets › DPEP1

DPEP1 (Dipeptidase 1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 2; Genitourinary, Cardiovascular, Oncology; next expected readout Mar 2027.

Hydrolyzes a wide range of dipeptides including the conversion of leukotriene D4 to leukotriene E4. Hydrolyzes cystinyl-bis-glycine (cys-bis-gly) formed during glutathione degradation. (UniProt, P16444)

Open in Phaseline: the race on DPEP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Arch BiopartnersLSALT Peptide
Binds to dipeptidase-1 (DPEP1) and inhibits leukocyte recruitment
DPEP1Phase 2Acute Kidney InjuryMar 2027
Matthew JamesCilastatin
Renal dipeptidase inhibitor
DPEP1Phase 2Acute Kidney InjuryDec 2027
Hospital General Universitario Gregorio Marañoncilastatin
Renal dipeptidase inhibitor
DPEP1Phase 2Debulking Surgery for Ovarian CancerOct 2028

Conditions

Acute Kidney Injury (2) Debulking Surgery for Ovarian Cancer (1)

Modalities

protein or peptide (2), small molecule (1)

Companies

Matthew James (1) Arch Biopartners (1) Hospital General Universitario Gregorio Marañon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.